2-(2-bromophenyl)-5-(pyridin-3-yl)-1,3,4-oxadiazole | 145731-84-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-bromophenyl)-5-(pyridin-3-yl)-1,3,4-oxadiazole
• 英文别名: 3-[5-(2-Bromophenyl)-1,3,4-oxadiazol-2-yl]pyridine；2-(2-bromophenyl)-5-pyridin-3-yl-1,3,4-oxadiazole
• CAS: 145731-84-6
• 化学式: C₁₃H₈BrN₃O
• 分子量: 302.13
• InChiKey: CCPYCXAUSQZJHG-UHFFFAOYSA-N

物化性质

• 熔点：
  102-114 °C
• 沸点：
  456.4±55.0 °C(Predicted)
• 密度：
  1.520±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-吡啶甲酰肼 、 2-溴苯甲酸 在 三氯氧磷 作用下， 反应 0.2h， 以92%的产率得到2-(2-bromophenyl)-5-(pyridin-3-yl)-1,3,4-oxadiazole
  参考文献：
  名称：

  Structure–activity relationships of tyrosinase inhibitory combinatorial library of 2,5-disubstituted-1,3,4-oxadiazole analogues

  摘要：

  Here the tyrosinase inhibition studies of library of 2,5-disubstituted-1,3,4-oxadiazoles have been reported and their structure-activity relationship (SAR) also have been discussed. The library of the oxadiazoles was synthesized under the microwave irradiation and was structures of these were characterized by different spectral techniques. From this study it could be concluded that for a better inhibition of tyrosinase, electronegative substitution is essential as most probably the active site of the enzyme contain some hydrophobic site and position is also very important for the inhibition purposes due to the conformational space. The electronegativity of the compounds is somewhat proportional to the inhibitory activity. The compound 3e (3 '-[5-(4 '-bromophenyl)-1,3,4-oxadiazol-2-yl]pyridine) exhibited most potent (IC50 = 2.18 mu M) inhibition against the enzyme tyrosinase which is more potent than the standard potent inhibitor L-mimosine IC50 = 3.68 mu M). This molecule can be the best candidate as a lead compound for further development of drug for the treatments of several skin disorders. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.012

文献信息

• HETEROCYCLIC COMPOUNDS AND THEIR METHODS OF USE
  申请人：Lee Chih-Hung

  公开号：US20080255203A1

  公开（公告）日：2008-10-16

  The invention relates to heterocyclic derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions. The heterocyclic derivatives, more particularly can be substituted oxadiazole compounds and derivatives thereof.

  本发明涉及杂环衍生物、含有这些化合物的组合物以及使用这些化合物和组合物预防或治疗疾病和障碍的方法。这些杂环衍生物，更具体地说，可以是取代的噁唑烷化合物及其衍生物。
• Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof
  申请人：Ji Jianguo

  公开号：US20080269236A1

  公开（公告）日：2008-10-30

  The invention relates to 1,2,4 oxadiazole compounds and analogs thereof, represented by formula (II), and compositions and methods of use thereof.

  本发明涉及1,2,4-噁二唑化合物及其类似物，由式（II）所表示，以及其组合物和使用方法。
• Pharmaceutical compositions and their methods of use
  申请人：Gopalakrishnan Murali

  公开号：US20080167286A1

  公开（公告）日：2008-07-10

  The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

  本发明涉及一种包含神经元烟碱受体配体和α4β2正向变构调节剂的组合物，以及使用该组合物的方法和相关制品。
• PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE
  申请人：Gopalakrishnan Murali

  公开号：US20110190314A1

  公开（公告）日：2011-08-04

  The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

  本发明涉及一种包含神经元烟碱受体配体和α4β2正向变构调节剂的组合物，使用该组合物的方法以及相关的制造物品。
• Pharmaceutical Compositions for the Treatment of Pain
  申请人：Gopalakrishnan Murali

  公开号：US20100305086A1

  公开（公告）日：2010-12-02

  This invention discloses a method of treatment of osteoarthritis pain by administration of a composition containing a nicotinic acetylcholine receptor ligand and a nicotinic acetylcholine receptor subtype α4β2 allosteric modulator. The present application also relates to compositions comprising such compounds for use in treating pain and related disorders mediated by controlling neurotransmitter release in a subject.

  本发明披露了一种治疗骨关节炎疼痛的方法，通过给予含有一种烟碱乙酰胆碱受体配体和一种烟碱乙酰胆碱受体亚型α4β2变构调节剂的组合物来进行治疗。本申请还涉及包含这些化合物的组合物，用于治疗控制受体内神经递质释放介导的疼痛和相关疾病。